Eight-year experience of using HTA in drug reimbursement: South Korea
详细信息 查看全文
- 作者：Eun-Young Baea ; b ; eybae@gnu.ac.kr" class="auth_mail" title="E-mail the corresponding author ; Ji-Min Hongc ; Hye-Young Kwond ; Suhyun Jangc ; Hye-Jae Leee ; SeungJin Baef ; Bong-Min Yangc
- 关键词：Accountability ; Drug reimbursement ; South Korea ; Economic evaluation ; Health technology assessment
- 刊名：Health Policy
- 出版年：2016
- 出版时间：June 2016
- 年：2016
- 卷：120
- 期：6
- 页码：612-620
- 全文大小：600 K
文摘
- •
As of 2014, 69.2% of submitted drugs were recommended to be listed.
- •
Only 26.9% of submitted drugs were clinically improved and required economic evaluations.
- •
Stakeholders agreed the consistency of reimbursement decision-making has improved since 2007.
- •
Accessibility to new drugs has decreased since 2007.
- •
Stakeholders would like to see improved public access to decision-making information.